Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 6/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | FABP4 | P15090 | 2/20 | 0.49 |
| ▸ | CXCR2 | P25025 | 3/20 | 0.48 |
| ▸ | CLCN2 | P51788 | 2/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7571715 | 0.85 | TAS2R14 (0.56) | TAS2R14FABP4CXCR2CLCN2AKR1C3 | |
| SCHEMBL1358523 | 0.75 | TAS2R14 (0.75) | TAS2R14FABP4CLCN2AKR1C3AKR1C2 | |
| SCHEMBL7571639 | 0.72 | CXCR2 (0.49) | CXCR2MEN1ALDH1A1KMT2A | |
| SCHEMBL8558161 | 0.71 | TAS2R14 (0.60) | TAS2R14FABP4CXCR2CLCN2AKR1C3 | |
| SCHEMBL11542345 | 0.71 | CXCR2 (0.53) | FABP4CXCR2MEN1ALDH1A1KMT2A | |
| SCHEMBL7568734 | 0.70 | CLCN2 (0.53) | TAS2R14FABP4CXCR2CLCN2AKR1C3 | |
| SCHEMBL11178354 | 0.70 | TAS2R14 (0.55) | TAS2R14FABP4CXCR2CLCN2MEN1 | |
| SCHEMBL7586739 | 0.70 | CXCR2 (0.47) | TAS2R14FABP4CXCR2AKR1C3AKR1C2 | |
| SCHEMBL15925029 | 0.69 | RXFP1 (0.57) | TAS2R14SMN1; SMN2FABP4CLCN2MEN1 | |
| SCHEMBL11347362 | 0.68 | TAS2R14 (0.72) | TAS2R14FABP4CLCN2AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6413996-B2 | CHLORIDE CHANNEL BLOCKERS; FOR TREATMENT OF SICKLE CELL ANAEMIA, BRAIN OEDEMA FOLLOWING ISCHAEMIA OR TUMOURS, DIARRHOEA, HYPERTENSION (DIURETIC), OSTEOPOROSIS, BONE METASTASIZING CANCERS | NEUROSEARCH A/S (DK) | 2002-07-02 | — | — | US | disclosed |
| US-20010056092-A1 | Diaminocyclobutene-3,4-dione derivatives, their preparation and use | ANIONA APS (DK) | 2001-12-27 | — | — | US | disclosed |
| EP-1117633-A1 | DIAMINOCYCLOBUTENE-3,4-DIONE DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000020378-A1 | DIAMINOCYCLOBUTENE-3,4-DIONE DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056092-A1 | Diaminocyclobutene-3,4-dione derivatives, their preparation and use | HCN4, CLIC1, KCNB1 | TAS2R14 2116/4885SMN1; SMN2 3899/4885FABP4 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.